FR13C0029I2 - COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - Google Patents

COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Info

Publication number
FR13C0029I2
FR13C0029I2 FR13C0029C FR13C0029C FR13C0029I2 FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2 FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 C FR13C0029 C FR 13C0029C FR 13C0029 I2 FR13C0029 I2 FR 13C0029I2
Authority
FR
France
Prior art keywords
compositions
treatment
gastrointestinal disorders
gastrointestinal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0029C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of FR13C0029I1 publication Critical patent/FR13C0029I1/en
Application granted granted Critical
Publication of FR13C0029I2 publication Critical patent/FR13C0029I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
FR13C0029C 2003-01-28 2013-05-23 COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS Active FR13C0029I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (en) 2003-01-28 2004-01-28 Methods and compositions for the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
FR13C0029I1 FR13C0029I1 (en) 2013-07-05
FR13C0029I2 true FR13C0029I2 (en) 2024-04-19

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (en) 2003-01-28 2013-05-23 COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
FR13C0029C Active FR13C0029I2 (en) 2003-01-28 2013-05-23 COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR13C0030C Active FR13C0030I1 (en) 2003-01-28 2013-05-23 COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

Country Status (29)

Country Link
US (3) US20040266989A1 (en)
EP (3) EP2246360B1 (en)
JP (3) JP4584911B2 (en)
KR (2) KR101227626B1 (en)
CN (2) CN101787073B (en)
AT (2) ATE365174T1 (en)
AU (2) AU2004210161B2 (en)
BE (1) BE2013C032I2 (en)
BR (2) BRPI0407071B8 (en)
CA (1) CA2514507C (en)
CY (5) CY1110905T1 (en)
DE (2) DE602004007105T2 (en)
DK (3) DK1594517T3 (en)
ES (3) ES2387848T3 (en)
FR (2) FR13C0030I1 (en)
HK (1) HK1078768A1 (en)
HU (1) HUS1300022I1 (en)
IL (2) IL169863A (en)
LT (1) LTC1594517I2 (en)
LU (2) LU92200I2 (en)
MX (1) MXPA05008097A (en)
NL (1) NL300593I2 (en)
NO (3) NO334112B1 (en)
NZ (2) NZ541595A (en)
PT (3) PT1594517E (en)
RU (2) RU2543350C2 (en)
SG (2) SG192300A1 (en)
SI (3) SI1911763T1 (en)
WO (1) WO2004069165A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078683A1 (en) 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN101787073B (en) 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 Methods and compositions for treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
JPWO2006046746A1 (en) * 2004-10-26 2008-05-22 味の素株式会社 Visceral pain prevention / treatment agent
WO2007022531A2 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PT1937262T (en) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composition for use in treating gastrointestinal dysmotility
CA2652677A1 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX2009011898A (en) * 2007-05-04 2009-11-18 Ironwood Pharmaceuticals Inc Compositions and methods for treating disorders associated with salt or fluid retention.
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005515A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Protein expression methods
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PL2328601T3 (en) * 2008-08-15 2020-07-13 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2010059733A1 (en) 2008-11-19 2010-05-27 Forest Laboratories Holdings Limited Crystalline form of linaclotide
CA2994066A1 (en) * 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
CN102482326A (en) * 2009-04-10 2012-05-30 科登制药科罗拉多公司 Process for isolating therapeutic peptide
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
WO2011020054A1 (en) 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
US20140179607A9 (en) 2009-11-09 2014-06-26 Ironwood Pharmaceuticals, Inc Treatments for Gastrointestinal Disorders
JP5984675B2 (en) * 2009-12-07 2016-09-06 アイアンウッド ファーマシューティカルズ インコーポレイテッド Gastrointestinal disorder therapy
UA108636C2 (en) 2010-02-17 2015-05-25 PEPTIDE
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2605786A4 (en) * 2010-06-09 2014-03-12 Combimab Inc Therapeutic peptides
SI2603232T1 (en) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc Formulations of guanylate cyclase c agonists and methods of use
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012155114A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Peptides derived from uroguanylin and their use in gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170804A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z5 (en) * 2011-07-07 2012-09-30 Эльвира АНДОН Method for treating acute ulcerative nonspecific colitis
JP6312592B2 (en) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド Treatment of digestive disorders
EA022546B1 (en) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Method for inhibiting growth of ehrlich carcinoma in laboratory animal
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
RU2528641C2 (en) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Method of treating patients with dyspepsia syndrome combined with overweight
CN102875655B (en) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 Linaclotide synthesis method
US20150361139A1 (en) 2013-01-30 2015-12-17 Sandoz Ag Crystalline form of linaclotide
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
PL3288578T3 (en) * 2015-05-01 2023-08-14 Ironwood Pharmaceuticals, Inc. Compositions for colon cleansing and the treatment of gastrointestinal disorders
WO2017160938A1 (en) * 2016-03-15 2017-09-21 The Regents Of The University Of California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASE ASSOCIATED WITH α8β1 INTEGRIN
CN107929718A (en) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 1 analogs of GLP and GC C receptor stimulating agent composition sustained-release preparations and preparation method thereof
CN117599320A (en) * 2018-10-23 2024-02-27 艾比科生物医学公司 Conveying device
CN109467606A (en) * 2018-11-15 2019-03-15 大连理工大学 A kind of escherichia coli enterotoxin STa-LTB-STb fusion protein and its encoding gene and application
JP2022533251A (en) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド Combinations to lower serum phosphate in patients
RU2712761C1 (en) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Agent for pulmonary endothelial regeneration stimulation at metabolic syndrome combined with chronic obstructive pulmonary disease
CN111265653B (en) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 Application of atrial natriuretic peptide in preparation of medicines for treating inflammatory bowel disease
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
WO2023144292A1 (en) 2022-01-28 2023-08-03 Fresenius Kabi Ipsum S.R.L. Process for the preparation of linaclotide

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US266989A (en) * 1882-11-07 Automatic fire
US73628A (en) * 1868-01-21 mitchell
US32684A (en) * 1861-07-02 Stump-extkactob
US258687A (en) * 1882-05-30 Grain-binder
US232013A (en) * 1880-09-07 Henry h
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (en) 1987-02-05 1990-03-14 Rotta Research Lab OPTICALLY ACTIVE DERIVATIVES OF ACID 5 PENTILAMINE 5 OXO PENTANOIC R WITH ANTAGONIST ACTIVITY OF THE CHOLECISTOKININ AND PROCEDURE FOR THEIR PREPARATION
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (en) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (en) 1991-04-02 1994-12-23 Logeais Labor Jacques NOVEL N-CYCLOHEXYL BENZAMIDES OR THIOBENZAMIDES DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS.
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
RU2194760C2 (en) * 1991-12-02 2002-12-20 Кор Терапьютикс, Инк. Immunoglobulin polypeptide, its fragment, composition, strain of hybrid cultured cells, method of polypeptide preparing
SG50624A1 (en) 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
SK74495A3 (en) 1993-01-06 1997-01-08 Kinerton Ltd Ionic molecular conjugates of biodegradable polyesters with bioactive polypeptides and a method of preparation thereof
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
CA2174928C (en) * 1993-10-26 2011-08-16 Scott A. Waldman Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
EP1336409B1 (en) 1995-06-27 2007-04-11 Eisai R&D Management Co., Ltd. Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
TR199800924T2 (en) 1995-11-24 1998-08-21 Smithkline Beecham S.P.A. Quinoline t�revleri.
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
DE69731623D1 (en) 1996-04-23 2004-12-23 Ipsen Mfg Ireland Ltd Acidic polylactic acid polymers
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
PT975347E (en) 1997-02-28 2008-05-23 Nycomed Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
ATE273996T1 (en) 1997-09-12 2004-09-15 Pharis Biotec Gmbh COMPOSITION FOR THE THERAPY OF DIABETES MELLITUS AND OBESITY
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (en) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl COMPOSITIONS INCLUDING A PEPTIDE AND POLYLACTIC-GLYCOLIC ACID FOR THE PREPARATION OF SUBCUTANEOUS IMPLANTS HAVING A PROLONGED
ATE291927T1 (en) 1999-06-23 2005-04-15 Pasteur Institut PEPTIDES FOR THE TREATMENT OF IMMEDIATE INTERPERSONAL AND BEHAVIORAL DISORDERS
DK1204429T3 (en) 1999-08-18 2004-03-08 Sod Conseils Rech Applic Preparation for delayed release of a peptide
SE9903291D0 (en) 1999-09-15 1999-09-15 Astra Ab New process
JP2003516316A (en) 1999-10-06 2003-05-13 ファルマシア コーポレイション Uroganiline as an intestinal cancer inhibitor
WO2001032180A2 (en) 1999-11-01 2001-05-10 Rodeva Limited Composition for treatment of constipation and irritable bowel syndrome
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU3580001A (en) 2000-03-01 2001-09-12 University College London Modulators of the endocannabinoid uptake and of the vallinoid receptors
EP1216707B1 (en) 2000-12-22 2005-02-09 Institut Pasteur Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
WO2002078683A1 (en) * 2001-03-29 2002-10-10 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US20040152868A1 (en) * 2001-03-30 2004-08-05 Larsen Bjarne Due Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
WO2002098912A2 (en) * 2001-06-05 2002-12-12 Yalcin Cetin Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
FR2830451B1 (en) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med USE OF THYMULIN-LIKE PEPTIDES (PAT) FOR THE MANUFACTURE OF PAIN MEDICATIONS
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
US20040121961A1 (en) * 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
US20050171014A1 (en) 2002-02-27 2005-08-04 Government Of The United States Of America, Represented By The Secretary, Department Of Health Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
CN100411618C (en) 2002-05-17 2008-08-20 迪欧加药品公司 Use of compounds that are effective as selective opiate receptor modulators
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
CN101787073B (en) * 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 Methods and compositions for treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson The use of gcc ligands
WO2007022531A2 (en) * 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
CY2013021I1 (en) 2020-05-29
NO20053864D0 (en) 2005-08-18
DE602004028678D1 (en) 2010-09-23
AU2004210161B2 (en) 2009-11-26
CN100589839C (en) 2010-02-17
ES2387848T3 (en) 2012-10-02
SI2246360T1 (en) 2012-10-30
EP1594517A2 (en) 2005-11-16
AU2004210161A1 (en) 2004-08-19
CY2013022I1 (en) 2020-05-29
NO2014013I1 (en) 2014-06-02
PT1911763E (en) 2010-11-18
BR122018074353B8 (en) 2023-05-02
WO2004069165A2 (en) 2004-08-19
RU2763796C2 (en) 2022-01-11
RU2005127058A (en) 2006-03-10
NL300593I1 (en) 2015-10-21
RU2014153593A3 (en) 2018-08-06
FR13C0030I1 (en) 2013-07-05
ATE365174T1 (en) 2007-07-15
SI1594517T1 (en) 2007-10-31
US8080526B2 (en) 2011-12-20
BE2013C032I2 (en) 2023-08-22
KR101227626B1 (en) 2013-02-01
NL300593I2 (en) 2020-04-15
US20090005534A1 (en) 2009-01-01
HK1078768A1 (en) 2006-03-24
DK1594517T3 (en) 2007-10-29
CN101787073A (en) 2010-07-28
EP1594517B1 (en) 2007-06-20
AU2009235993A1 (en) 2009-11-26
CN101787073B (en) 2013-12-25
JP5563384B2 (en) 2014-07-30
US20040266989A1 (en) 2004-12-30
IL221380A0 (en) 2012-09-24
JP4584911B2 (en) 2010-11-24
EP2246360A1 (en) 2010-11-03
IL169863A (en) 2012-10-31
JP2013116910A (en) 2013-06-13
LU92201I2 (en) 2013-11-22
ATE477268T1 (en) 2010-08-15
FR13C0029I1 (en) 2013-07-05
JP2010222377A (en) 2010-10-07
CA2514507A1 (en) 2004-08-19
NO334112B1 (en) 2013-12-09
DE602004007105T2 (en) 2008-02-28
BRPI0407071B8 (en) 2021-05-25
HUS1300022I1 (en) 2019-11-28
RU2014153593A (en) 2016-07-20
EP1594517A4 (en) 2006-03-29
KR101227627B1 (en) 2013-01-31
LTC1594517I2 (en) 2020-03-10
NZ570134A (en) 2010-02-26
NO20053864L (en) 2005-10-26
RU2008147983A (en) 2010-06-10
JP5748791B2 (en) 2015-07-15
AU2009235993B2 (en) 2013-07-04
CY1113217T1 (en) 2016-04-13
EP1911763A2 (en) 2008-04-16
CN1795007A (en) 2006-06-28
CY1110905T1 (en) 2015-06-10
DK1911763T3 (en) 2010-11-15
US7704947B2 (en) 2010-04-27
NO20130460L (en) 2005-10-26
MXPA05008097A (en) 2006-02-08
KR20050106404A (en) 2005-11-09
DK2246360T3 (en) 2012-08-13
US20110124583A1 (en) 2011-05-26
LU92200I2 (en) 2024-03-21
NO336768B1 (en) 2015-11-02
SG168407A1 (en) 2011-02-28
EP1911763A3 (en) 2008-06-25
EP1911763B1 (en) 2010-08-11
RU2353383C2 (en) 2009-04-27
PT2246360E (en) 2012-08-31
BR122018074353B1 (en) 2019-07-16
PT1594517E (en) 2007-07-20
WO2004069165A3 (en) 2005-03-17
SI1911763T1 (en) 2010-11-30
NZ541595A (en) 2008-08-29
LU92200I1 (en) 2020-06-02
EP2246360B1 (en) 2012-06-27
RU2543350C2 (en) 2015-02-27
CY1111058T1 (en) 2015-06-11
KR20110114682A (en) 2011-10-19
NO2014013I2 (en) 2014-05-21
BRPI0407071A (en) 2006-01-24
ES2285417T3 (en) 2007-11-16
ES2350123T3 (en) 2011-01-18
DE602004007105D1 (en) 2007-08-02
JP2006516631A (en) 2006-07-06
CA2514507C (en) 2012-03-20
SG192300A1 (en) 2013-08-30
BRPI0407071B1 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
FR13C0029I2 (en) COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
MA28791B1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
MA28481B1 (en) Imidazole derivatives for the treatment of neurodegenerative disorders
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
IS7099A (en) Compounds for the treatment of inflammatory disorders
MA29098B1 (en) COMPOSITIONS FOR THE TREATMENT OF HCV
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
PT1644021E (en) Methods and compositions for the treatment of gastrointestinal disorders
FR22C1033I1 (en) Use of dihydroimidazolones for the treatment of dogs
EP1615664A4 (en) Pharmaceutical composition for treatment of immunological disorders
MA28493B1 (en) Sulfonamides for the treatment of neurodegenerative disorders
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
EP1658072A4 (en) Compounds for the treatment of neurodegenerative disorders
MA29085B1 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR THE TREATMENT OF SLEEP DISORDERS
FR2860154B1 (en) COMPOSITION FOR THE TREATMENT OF MALE BREATH
FR2835851B1 (en) COMPOSITION FOR THE TREATMENT OF MAGNESIUM ALLOYS
FR2924593B1 (en) BONE PLATE FOR THE TREATMENT OF THE LOWER END OF THE CUBITUS
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
FR2884714B1 (en) USE OF AGOMELATIN FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF BIPOLAR DISORDERS
FR2887456B1 (en) "COMPOSITION FOR THE TREATMENT OF THE SUMMER DERMITE"
FR2868312B1 (en) PATCH FOR THE TREATMENT OF LIP
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
MA28513B1 (en) PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS
HK1094698A1 (en) Beta-lactams for the treatment of cns disorders
FR2851247B1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DEGENERATIVE PATHOLOGIES